vs

Side-by-side financial comparison of Alpha Metallurgical Resources, Inc. (AMR) and BIOCRYST PHARMACEUTICALS INC (BCRX). Click either name above to swap in a different company.

Alpha Metallurgical Resources, Inc. is the larger business by last-quarter revenue ($519.1M vs $406.6M, roughly 1.3× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs -3.3%, a 63.8% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs -15.7%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $-10.0M). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs -22.4%).

Alpha Metallurgical Resources, formerly Contura Energy, is a leading coal supplier with underground and surface coal mining complexes across Northern and Central Appalachia. Contura owns large coal basins in Pennsylvania, Virginia and West Virginia which supply both metallurgical coal to produce steel and thermal coal to generate power.

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

AMR vs BCRX — Head-to-Head

Bigger by revenue
AMR
AMR
1.3× larger
AMR
$519.1M
$406.6M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+224.7% gap
BCRX
209.1%
-15.7%
AMR
Higher net margin
BCRX
BCRX
63.8% more per $
BCRX
60.5%
-3.3%
AMR
More free cash flow
BCRX
BCRX
$301.1M more FCF
BCRX
$291.2M
$-10.0M
AMR
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
-22.4%
AMR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMR
AMR
BCRX
BCRX
Revenue
$519.1M
$406.6M
Net Profit
$-17.3M
$245.8M
Gross Margin
97.7%
Operating Margin
-4.1%
64.0%
Net Margin
-3.3%
60.5%
Revenue YoY
-15.7%
209.1%
Net Profit YoY
-711.2%
1017.5%
EPS (diluted)
$-1.35
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMR
AMR
BCRX
BCRX
Q4 25
$519.1M
$406.6M
Q3 25
$525.2M
$159.4M
Q2 25
$548.7M
$163.4M
Q1 25
$529.7M
$145.5M
Q4 24
$615.4M
$131.5M
Q3 24
$669.8M
$117.1M
Q2 24
$800.1M
$109.3M
Q1 24
$861.3M
$92.8M
Net Profit
AMR
AMR
BCRX
BCRX
Q4 25
$-17.3M
$245.8M
Q3 25
$-5.5M
$12.9M
Q2 25
$-5.0M
$5.1M
Q1 25
$-33.9M
$32.0K
Q4 24
$-2.1M
$-26.8M
Q3 24
$3.8M
$-14.0M
Q2 24
$58.9M
$-12.7M
Q1 24
$127.0M
$-35.4M
Gross Margin
AMR
AMR
BCRX
BCRX
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Q1 24
98.6%
Operating Margin
AMR
AMR
BCRX
BCRX
Q4 25
-4.1%
64.0%
Q3 25
-0.5%
18.6%
Q2 25
0.5%
18.2%
Q1 25
-7.6%
14.6%
Q4 24
1.6%
-3.4%
Q3 24
0.8%
6.6%
Q2 24
8.8%
8.0%
Q1 24
16.5%
-15.6%
Net Margin
AMR
AMR
BCRX
BCRX
Q4 25
-3.3%
60.5%
Q3 25
-1.1%
8.1%
Q2 25
-0.9%
3.1%
Q1 25
-6.4%
0.0%
Q4 24
-0.3%
-20.4%
Q3 24
0.6%
-12.0%
Q2 24
7.4%
-11.6%
Q1 24
14.7%
-38.1%
EPS (diluted)
AMR
AMR
BCRX
BCRX
Q4 25
$-1.35
$1.13
Q3 25
$-0.42
$0.06
Q2 25
$-0.38
$0.02
Q1 25
$-2.60
$0.00
Q4 24
$-0.09
$-0.13
Q3 24
$0.29
$-0.07
Q2 24
$4.49
$-0.06
Q1 24
$9.59
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMR
AMR
BCRX
BCRX
Cash + ST InvestmentsLiquidity on hand
$415.6M
$274.7M
Total DebtLower is stronger
$9.8M
Stockholders' EquityBook value
$1.5B
$-119.2M
Total Assets
$2.3B
$514.2M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMR
AMR
BCRX
BCRX
Q4 25
$415.6M
$274.7M
Q3 25
$457.9M
$212.9M
Q2 25
$449.0M
$260.0M
Q1 25
$448.0M
$295.1M
Q4 24
$481.6M
$320.9M
Q3 24
$484.6M
$96.8M
Q2 24
$336.1M
$78.4M
Q1 24
$269.4M
$84.3M
Total Debt
AMR
AMR
BCRX
BCRX
Q4 25
$9.8M
Q3 25
$2.9M
Q2 25
$3.1M
Q1 25
$2.4M
Q4 24
$2.9M
Q3 24
$3.6M
Q2 24
$5.3M
Q1 24
$6.0M
Stockholders' Equity
AMR
AMR
BCRX
BCRX
Q4 25
$1.5B
$-119.2M
Q3 25
$1.6B
$-387.9M
Q2 25
$1.6B
$-421.6M
Q1 25
$1.6B
$-451.9M
Q4 24
$1.6B
$-475.9M
Q3 24
$1.7B
$-468.6M
Q2 24
$1.6B
$-475.6M
Q1 24
$1.6B
$-476.2M
Total Assets
AMR
AMR
BCRX
BCRX
Q4 25
$2.3B
$514.2M
Q3 25
$2.3B
$446.4M
Q2 25
$2.4B
$457.2M
Q1 25
$2.4B
$480.0M
Q4 24
$2.4B
$490.4M
Q3 24
$2.5B
$491.3M
Q2 24
$2.5B
$472.4M
Q1 24
$2.5B
$467.9M
Debt / Equity
AMR
AMR
BCRX
BCRX
Q4 25
0.01×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMR
AMR
BCRX
BCRX
Operating Cash FlowLast quarter
$19.0M
$292.0M
Free Cash FlowOCF − Capex
$-10.0M
$291.2M
FCF MarginFCF / Revenue
-1.9%
71.6%
Capex IntensityCapex / Revenue
5.6%
0.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$17.8M
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMR
AMR
BCRX
BCRX
Q4 25
$19.0M
$292.0M
Q3 25
$50.5M
$41.6M
Q2 25
$53.2M
$41.3M
Q1 25
$22.2M
$-27.5M
Q4 24
$56.3M
$-5.2M
Q3 24
$189.5M
$8.2M
Q2 24
$138.1M
$-1.4M
Q1 24
$196.1M
$-53.7M
Free Cash Flow
AMR
AMR
BCRX
BCRX
Q4 25
$-10.0M
$291.2M
Q3 25
$25.4M
$40.3M
Q2 25
$18.6M
$41.1M
Q1 25
$-16.3M
$-27.7M
Q4 24
$13.6M
$-5.9M
Q3 24
$158.0M
$8.2M
Q2 24
$77.0M
$-1.5M
Q1 24
$132.5M
$-53.9M
FCF Margin
AMR
AMR
BCRX
BCRX
Q4 25
-1.9%
71.6%
Q3 25
4.8%
25.3%
Q2 25
3.4%
25.2%
Q1 25
-3.1%
-19.0%
Q4 24
2.2%
-4.5%
Q3 24
23.6%
7.0%
Q2 24
9.6%
-1.4%
Q1 24
15.4%
-58.1%
Capex Intensity
AMR
AMR
BCRX
BCRX
Q4 25
5.6%
0.2%
Q3 25
4.8%
0.8%
Q2 25
6.3%
0.1%
Q1 25
7.3%
0.1%
Q4 24
6.9%
0.5%
Q3 24
4.7%
0.1%
Q2 24
7.6%
0.1%
Q1 24
7.4%
0.3%
Cash Conversion
AMR
AMR
BCRX
BCRX
Q4 25
1.19×
Q3 25
3.23×
Q2 25
8.12×
Q1 25
-859.91×
Q4 24
Q3 24
49.81×
Q2 24
2.34×
Q1 24
1.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons